surmount-1 trial tirzepatide obesity without diabetes For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Tirzepatide for Obesity: Highlights from
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10






:max_bytes(150000):strip_icc()/health-GettyImages-1498826563-72ccaac18ecf41e49988eccfc823270f.jpg)














